heart failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. BMI 18-30 kg/m2; 3. LVEF< 0.40; 4. NYHA I~III; 5. Clinical symptoms are stable for at least 2 weeks; 6. The dose of angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist/angiotensin receptor enkephinase inhibitor (ACEI/ARB/ARNI), beta-blocker, aldosterone inhibitor and other drugs was stabilized for at least 2 weeks 7. Agree to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. Have a history of heart implant device in the last 6 weeks, or have a recent heart implant device plan or heart transplant plan; 2. Acute coronary syndrome within 6 weeks; 3. Severe valvular heart disease, congenital heart disease, severe hypertrophic obstructive cardiomyopathy, acute myocarditis/pericarditis, intracardiac thrombosis, primary pulmonary hypertension, perinatal cardiomyopathy, thyroid heart disease; 4. Implanted pacemaker with no frequency response function, or set the discharge threshold of ICD lower than the heart rate during exercise; 5. Severe arrhythmias such as ventricular tachycardia, frequent multi-source premature ventricular beats, high atrioventricular block and significant QT interval prolongation occurred during exercise test; 6. Contraindications to exercise training: uncontrolled hypertension (systolic blood pressure >200mmHg and/or diastolic blood pressure >110mmHg); 7. Progressive dyspnea or loss of exercise endurance in the last 3-5 days at rest; 8. Myocardial ischemia under low power exercise load (<2MET, or <50W); 9. Uncontrolled diabetes; 10. Recent embolism; 11.Thrombophlebitis; 12. New atrial fibrillation or atrial flutter, etc., and other conditions not suitable for sports training; 13. Severe liver and kidney dysfunction, liver function more than three times the normal value, eGFR less than 30mL/min/1.73m2; 14. Currently suffering from severe mental illness, severe respiratory disorders, severe hematological diseases, severe nervous and neuromuscular diseases, severe metabolic and endocrine diseases, malignant neoplasms, severe autoimmune diseases, complicated with systemic infections and other acute systemic diseases; 15. Other clinical studies have been included to influence the results of this study; 16. Women who are pregnant or preparing to become pregnant, and women who are breastfeeding; 17. The researchers determined that the patients were not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak oxygen uptake;Minnesota Heart Failure Quality of Life Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anaerobic threshold oxygen uptake;Six minutes walking distance;left ventricular ejection fraction;Amino-terminal brain natriuretic peptide (NT-proBNP);Item 9 Patient Health Questionnaire Score (PHQ-9);Generalized Anxiety Disorder Scale score (GAD-7);all-cause mortality;Cardiovascular causes of death;all-cause hospitalization;Hospitalization for heart failure;Major cardiovascular events (MACEs); | — |
Countries
China
Contacts
Shanghai Tongji Hospital